贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾

本文报道1例女性肺腺癌患者,表皮生长因子受体（epidermal growth factor receptor,EGFR）、V-Ki-ras2鼠Kirsten肉瘤病毒致癌基因同源物（V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog,KRAS）基因突变及棘皮动物微管相关类蛋白4与间变性淋巴瘤激酶融合基因（chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase,EML4-ALK）检测结果均为阴性;一线接受贝伐珠单抗（15mg/kg）联合常规剂量紫杉醇、...

Full description

Saved in:
Bibliographic Details
Published in中国肺癌杂志 Vol. 16; no. 6; pp. 325 - 329
Main Author 武玮 唐俊舫 吴羽华 朱允中 徐丽艳 史鹤玲 孟弃逸 刘赞 郭丽丽 陶虹 李明智 刘喆
Format Journal Article
LanguageChinese
Published 首都医科大学附属北京胸科医院肿瘤科, 北京,101149 2013
Subjects
化疗
肺肿瘤
贝伐珠单抗
Chemotherapy
化疗
肺肿瘤
贝伐珠单抗
Bevacizumab
Lung neoplasms
Online AccessGet full text
ISSN1009-3419
1999-6187
DOI10.3779/j.issn.1009-3419.2013.06.10

Cover

More Information
Summary:本文报道1例女性肺腺癌患者,表皮生长因子受体（epidermal growth factor receptor,EGFR）、V-Ki-ras2鼠Kirsten肉瘤病毒致癌基因同源物（V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog,KRAS）基因突变及棘皮动物微管相关类蛋白4与间变性淋巴瘤激酶融合基因（chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase,EML4-ALK）检测结果均为阴性;一线接受贝伐珠单抗（15mg/kg）联合常规剂量紫杉醇、卡铂方案6周期化疗以及后续贝伐珠单抗的维持治疗。共应用贝伐珠单抗42周期,应用总剂量达44,730mg,患者的无进展生存期（progres-sion-free survival,PFS）长达39个月,患者的长期生存获益远超出了不良反应所带来的危害。
Bibliography:Bevacizumab; Chemotherapy; Lung neoplasms
Wei WU, Junfang TANG, Yuhua WU, Yunzhong ZHU, Liyan XU, Heling SHI, Qiyi MENG, Zan LIU, Lili GUO, Hong TAO, Mingzhi LI, Zhe LIU（ Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China ）
We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor （EGFR）, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog （KRAS） gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase （EML4-ALK） gene rearrangement and treated with bevacizumab （15 mg/kg） in combination with 6 cycles of conventional doses of paclitaxel and carboplatin chemotherapy. She was then treated with maintenance bevacizumab for a total of 42 cycles, the total dose of bevacizumab is 44,730 mg. The progression-free survival was 39 months. Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer （NSCLC） is safe and its be
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2013.06.10